On September 7, 2021 Invectys Inc. a clinical-stage immunotherapy company headquartered in Houston and dedicated to the development of a new generation of products for cancer patients, reported that Praveen Tyle, Ph.D., Invectys Inc. President and CEO will participate in the H.C, Wainwright 23rd Annual Global Investment Conference to be held virtually September 13-15, 2021 (Press release, Invectys, SEP 7, 2021, https://www.invectys.com/non-classe/invectys-inc-to-participate-in-the-2021-h-c-wainwright-23rd-annual-global-investment-conference-september-13-15-2021/ [SID1234587288]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Tyle will present on the topic titled "Novel Approaches to Tumor Eradication". Invectys, Inc focuses on a multi-modality approach to targeting HLA-G on tumor cells and also an approach with universal tumor antigen telomerase. The presentation is virtual and will be available on demand for the duration of the conference.

If you would like to set up a meeting, feel free to contact us at [email protected].

On September 7, 2021 Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology company, developing new precision medicine treatment options for cancer patients in indications with the greatest unmet medical need including KRAS-mutated colorectal cancer, pancreatic cancer, and castrate-resistant prostate cancer, reported that Mark Erlander, Ph.D., chief executive officer and James Levine, chief financial officer, of Cardiff Oncology, will present and participate in virtual 1×1 investor meetings at the H.C. Wainwright 23rd Annual Global Investment Conference and the 2021 Cantor Virtual Global Healthcare Conference, taking place September 13 – 15th 2021, and September 27 – 30th 2021, respectively (Press release, Cardiff Oncology, SEP 7, 2021, View Source [SID1234587287]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details on the presentations can be found below.

H.C. Wainwright 23rd Annual Global Investment Conference
Presentation Date: Available on-demand starting at 7:00 AM ET on September 13, 2021
Webcast Link:
View Source

2021 Cantor Virtual Global Healthcare Conference
Presentation Date: Thursday, September 30, 2021
Time: 2:40 – 3:10 PM ET
Webcast Link:
View Source

Replays of the presentations will be available by visiting the "Events" section of the Cardiff Oncology website after their conclusion and will be archived for 90 days.

On September 7, 2021 HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, reported that HOOKIPA’s management team will participate and present at the following upcoming virtual investor conferences (Press release, Hookipa Pharma, SEP 7, 2021, View Source [SID1234587286]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Morgan Stanley 19th Annual Global Healthcare Conference, September 9 – 10 and 13 – 15, 2021
Fireside Chat: September 10, 8:45am ET
H.C. Wainwright 23rd Annual Global Investment Conference, September 13 – 15, 2021
Presentation: September 13, 7:00am ET
2021 Cantor Virtual Global Healthcare Conference, September 27 – 30, 2021
Presentation: September 28, 8:00-8:30am ET in Track 7
Webcasts will be available within the Investors & Media section of HOOKIPA’s website at View Source Archived replays will be accessible for 30 days following each event.

On September 7, 2021 Orum Therapeutics, a biotechnology company pioneering the development of tumor-directed targeted protein degraders, reported that Sung Joo Lee, Ph.D., Founder and CEO of Orum Therapeutics, will present at Baird’s 2021 Global Healthcare Conference, on Tuesday, September 14th, 2021 at 10:50 a.m. ET (Press release, Orum Therapeutics, SEP 7, 2021, View Source [SID1234587285]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On September 7, 2021 Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer reported that it will present at upcoming investor conferences (Press release, Panbela Therapeutics, SEP 7, 2021, View Source;utm_medium=rss&utm_campaign=panbela-to-present-at-upcoming-investor-conferences [SID1234587284]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright 23rd Annual Global Investment Conference: September 13th to 15th, 2021

Presentation will be available on-demand beginning September 13, 2021
Webcast: View Source
Management will also host 1×1 investor meetings during the conference.

Oppenheimer Fall Healthcare Life Sciences & MedTech Summit: September 20-23

Presentation Date and Time: September 21, 2021, at 9:55am ET
Event link: View Source
Management will also host 1×1 investor meetings during the conference.

To learn more or to schedule a one-on-one meeting with management, please contact your conference representative or [email protected].

About SBP-101
SBP-101 is a proprietary polyamine analogue designed to induce polyamine metabolic inhibition (PMI) by exploiting an observed high affinity of the compound for pancreatic ductal adenocarcinoma and other tumors. The molecule has shown signals of tumor growth inhibition in clinical studies of US and Australian metastatic pancreatic cancer patients, suggesting potential complementary activity with an existing FDA-approved standard chemotherapy regimen. In data evaluated from clinical studies to date, SBP-101 has not shown exacerbation of bone marrow suppression and peripheral neuropathy, which can be chemotherapy-related adverse events. Recently observed serious visual adverse events have been evaluated and patients with a history of retinopathy or at risk of retinal detachment will be excluded from future SBP-101 studies. The safety data and PMI profile observed in the current Panbela sponsored clinical trial provides support for continued evaluation of SBP-101 in a randomized clinical trial. For more information, please visit View Source